Clinical Trial Update: Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating certolizumab pegol for induction of remission in Crohn's disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Pharma | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2010-12-30